Most Recent Articles by Marc Iskowitz
My hope is that all of us do a better job of focusing on value.
Each of this year's Influencers wields significant influence at a major health-related organization and boasts high-profile accomplishments, oftentimes ahead of the aforementioned pain-of- change curve.
And why the stories behind thalidomide, Naprosyn, AZT, cardiology stents, and Zaltrap still resonate.
Some innovations are still emerging, while others seem more elusive than ever. You'll find many moments whose impact resonates through time.
When the Career and Salary Survey made its debut, in 1987, Eli Lilly's Prozac led the list of mass-market drug launches and AIDS therapy had taken a big step forward with the approval of GlaxoSmithKline's AZT, a year earlier.
More Articles by Marc Iskowitz
- The 2017 pipeline report: What to know about next year's launches
- Five things for pharma marketers to know: Monday, November 28, 2016
- Lilly's branded app for Trulicity looks to address adherence
- Lawmakers cut CME exemption from 21st Century Cures Act
- Five things for pharma marketers to know: Tuesday, November 29, 2016
- Boehringer Ingelheim launches gamified support program
- Omnicom merges AgencyRx, Flashpoint and three other agencies to form DDB Health
- No free lunch for docs: Sponsored meals linked to more prescriptions
- Non-profit behind Free Killer Tan wants parents to practice sun safety
- Allergan draws on A-list celebs to drive engagement
- Prescription drug spending rises 9% in 2015, to $324 billion
- As users move to mobile, Google says they made 200 million queries for info about cancer drugs
- Five things for pharma marketers to know: Friday, December 2, 2016
- Mylan CEO defends EpiPen strategy, questions pricing model in the U.S.
- Five things for pharma marketers to know: Thursday, December 1, 2016